First multicenter study of modified release phosphatidylcholine LT-02 in ulcerative colitis: a randomized, placebo-controlled trial in mesalazine-refractory courses
Karner M, Kocjan A, Stein J, Schreiber S, von Boyen G, Uebel P, Schmidt C, Kupcinskas L, Dina I, Zuelch F, Keilhauer G, Stremmel W
Published in American Journal of Gastroenterology
Methodology
Multicenter randomized placebo-controlled trial of modified-release phosphatidylcholine LT-02 at three doses in mesalazine-refractory ulcerative colitis
Key Findings
Remission rates were higher with LT-02 than placebo, but the primary endpoint of change in disease activity did not reach significance for all doses
Conclusions
LT-02 shows promise in mesalazine-refractory ulcerative colitis but confirmatory trials are needed
Limitations
Mixed endpoint results; later phase III development did not confirm efficacy
Supplements Studied
Remission rates were higher with LT-02 than placebo, but the primary endpoint of change in disease activity did not reach significance for all doses
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.